Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics to take different approach to grass pollen jab

The next dose range study is planned to start next year with Allergy waiting until it hears the outcome of what’s called an End of Phase II meeting with the US Food & Drug Administration.
Allergy Therapeutics to take different approach to grass pollen jab
The company is developing a jab for those with an allergy to grass pollen.

Allergy Therapeutics plc (LON:AGY) said it will take a new approach to finding the optimal dose for its grass pollen inoculation ahead of phase III clinical trials in the US.

The dose ranging study, called G204, failed to find the optimal quantity of GrassMATAMPL required.

As a result it will use the process deployed during research on its Pollinex Quattro Birch product.

The next dose range study is planned to start next year with Allergy waiting until it hears the outcome of what’s called an End of Phase II meeting with the US Food & Drug Administration.

"Defining the optimal dose is part of late-stage product development and we will revisit dose evaluation as we recently successfully did with our PQ Birch product, using two separate and complimentary dose-ranging studies,” said chief executive Manuel Llobet.

“Additionally, the new findings of our Phase II EEC study will need to be discussed with FDA before deciding on the recommended dose for the following Phase III registration trial. 

“While still being determined to become the first company to introduce SCIT to the US, a deferred entry time into the market is now anticipated.”

GrassMATAMPL is an ultra-short course injection given at the start of the grass pollen fever that is being developed for hay fever sufferers.

Separately, the company revealed its European sales of are currently growing at 19% as “penetration” of its allergy products continued to grow.

Ian_55ae0ddd437b7.jpg
Why Invest In Allergy Therapeutics plc? Read More Here

Register here to be notified of future AGY Company articles
View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

Regeneus: Access latest PPT from Proactive's CEO Sessions
June 18 2017
John Martin discussed regenerative medicine with investors.
Novogen: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Dr James Garner talked clinical-stage programs with investors.
picture of drug research
June 05 2017
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use